CTCL Treatments - The Old and New - Part 2

Article

Part 2 of an overview and explanation of current cutaneous lymphoma treatments.

Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part two of a three part overview of treatments for cutaneous lymphoma.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
A panel of 3 experts on CML
Starting CML Treatment: Collaborative Choices for Better Outcomes
A panel of 3 experts on CML
Empowering CML Caregivers: Strategies and Support Systems
A panel of 3 experts on CML
Navigating CML: Tools to Empower Patients and Caregivers
A panel of 3 experts on CML
Understanding CML: Your Journey from Diagnosis to Treatment
Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma
Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma
Elizabeth Aronson
Elizabeth Aronson Breaks Down Data From Behind Talquetamab Approval in Multiple Myeloma
Shivani Gopalsami
Wheatley and Gopalsami Highlight the Value of Interdisciplinary Collaboration in HSCT Care
Donna Catamero
Donna Catamero Discusses Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis
Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis
Related Content
Aerial photo of four medical professionals talking in a huddle; two are wearing scrubs and two are wearing lab coats

Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden

Bridget Hoyt
Published: March 19th 2025 | Updated: March 19th 2025
Article

Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

Darlene Dobkowski, MA
February 3rd 2025
Article

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

green background with blue text indicating FDA and green text indicating approved with a green checkmark

FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS

Bridget Hoyt
January 24th 2025
Article

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

dark blue background with three people around a clip board

NCCN Recommends ctDNA Testing for MRD Assessment in DLBCL

Ashling Wahner
January 14th 2025
Article

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.